v3.26.1
GENERAL AND GOING CONCERN (Details Narrative) - USD ($)
1 Months Ended 9 Months Ended 12 Months Ended
Feb. 18, 2026
Jan. 31, 2026
Apr. 30, 2026
Apr. 30, 2025
Jul. 31, 2025
LineItemsOrganizationConsolidationAndPresentationOfFinancialStatements [Line Items]          
Accumulated deficit     $ 134,339,456   $ 111,755,564
Cash flows from operating activities     $ 22,692,452 $ 20,038,075  
Gross proceeds from equity   $ 30,000,000     $ 50,900,000
BriaPro Therapeutics Corp, [Member]          
LineItemsOrganizationConsolidationAndPresentationOfFinancialStatements [Line Items]          
Subsidiary, Ownership Percentage, Parent 78.00%        
Common Stock [Member]          
LineItemsOrganizationConsolidationAndPresentationOfFinancialStatements [Line Items]          
Stock Issued During Period, Shares, Other 23,972,589        
Bria Cell Therapeutics [Member]          
LineItemsOrganizationConsolidationAndPresentationOfFinancialStatements [Line Items]          
Fund for Research and development $ 3,000,000        
BriaPro Therapeutics Corp, [Member]          
LineItemsOrganizationConsolidationAndPresentationOfFinancialStatements [Line Items]          
Royalties percentage 2.00%